Flagler Health, a New York-based healthcare technology company, has successfully raised $50 million in a Series B financing round to expand its AI-native platform for musculoskeletal (MSK) care. This latest investment, led by Bessemer Venture Partners, brings the company's total funding to $63 million. The capital is earmarked to accelerate the adoption of its technology, which automates clinical and administrative operations for MSK practices across the United States.
Addressing Systemic Industry Challenges
The musculoskeletal sector represents a significant portion of the healthcare industry, with conditions affecting over half of U.S. adults and accounting for more than $400 billion in annual spending. Physicians in this field often face immense administrative burdens, spending a large majority of their time on tasks that do not directly generate revenue. This inefficiency creates financial pressure on practices and contributes to clinician burnout, impacting overall patient care.
Flagler Health aims to solve these structural problems by offering a comprehensive operating system rather than a tool for isolated tasks. CEO Albert Katz, a former MSK clinic operator, noted that issues like shrinking reimbursements and administrative overload are systemic, not simply workflow problems. The platform, developed by clinicians, is trained on a vast dataset of MSK patients to address these core economic and operational challenges.
Platform Integration and Proven Impact
A key feature of Flagler's technology is its ability to integrate directly with existing electronic medical record (EMR) systems. This seamless approach coordinates critical workflows, including patient triage, care management, billing, and communications, without requiring clinicians to adopt a separate system. By operating within the existing practice infrastructure, the platform minimizes disruption and avoids the steep learning curves associated with new software.
The company reports significant positive outcomes for practices utilizing its platform, with an average of $164,000 in additional annual revenue generated per provider. Furthermore, patient results are equally compelling, as 87% of individuals report improvements in pain, mood, sleep, or mobility. These metrics underscore Flagler's dual focus on enhancing practice profitability while simultaneously improving patient health outcomes.
Strategic Investment and National Expansion
The Series B round saw participation from notable investors including SignalFire, Alumni Ventures, and Streamlined, reflecting strong confidence in Flagler's mission. The infusion of capital will fuel the company's expansion across the U.S., building on its current presence where thousands of providers in over 36 states already use the technology. This strategic funding is designed to scale the company's proven model across a fragmented national market.
Investors were particularly drawn to the company's unique leadership, which combines deep healthcare operations experience with clinical authority and AI expertise. Bessemer partner Steve Kraus highlighted this rare combination as a critical factor in their decision to back the company. This blend of skills positions Flagler to effectively address one of the largest and most underserved markets in healthcare.
With its new funding, Flagler is focused on deepening its specialization within the MSK sector rather than diversifying into other medical fields. The company's strategy centers on leveraging its accumulated clinical data and EMR integrations to build an indispensable technology platform for orthopedic and pain management practices. This focused approach aims to establish Flagler as a key infrastructure provider for the entire MSK ecosystem.
In conclusion, Flagler Health's $50 million funding round marks a pivotal moment for the company and the musculoskeletal care industry. This investment will empower the company to scale its AI-driven platform, which is designed to alleviate administrative burdens and enhance revenue for healthcare providers. By improving both operational efficiency and patient outcomes, Flagler is well-positioned to become an essential partner for MSK practices nationwide.